CD38, a glycoprotein found abundantly on the surface of MM cells, serves as an ideal target for therapeutic interventions, such as monoclonal antibodies (daratumumab and isatuximab) [83, 172–174]. Here, CD38 is linked to Miyoshi myopathy.